Plant ID: NPO23156
Plant Latin Name: Maclura cochinchinensis
Taxonomy Genus: Maclura
Taxonomy Family: Moraceae
NCBI TaxonomyDB:
194324
Plant-of-the-World-Online:
n.a.
Thailand
TAS2R31; | |
ADORA3; | |
TSHR; | |
TDP1; | |
KCNA3; | |
ESR1; | |
RARA; | |
ABCB1; ABCG2; | |
LMNA; RAB9A; NPC1; HSP90AA1; MAPT; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
ATP-binding cassette | ABCB1 | P-glycoprotein 1 | P08183 | CHEMBL4302 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group B | RARA | Retinoic acid receptor alpha | P10276 | CHEMBL2055 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Potassium channels | KCNA3 | Voltage-gated potassium channel subunit Kv1.3 | P22001 | CHEMBL4633 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Taste receptor (taste family GPCR) | TAS2R31 | Taste receptor type 2 member 31 | P59538 | CHEMBL2034804 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | HSP90AA1 | Heat shock protein HSP 90-alpha | P07900 | CHEMBL3880 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.138E-14 | 1.239E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.859E-13 | 8.098E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 4.763E-13 | 1.482E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.005E-12 | 5.458E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.221E-11 | 2.216E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.811E-11 | 6.384E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 9.011E-10 | 1.033E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 9.011E-10 | 1.033E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.736E-09 | 6.111E-06 | CYP1A2, CYP2C9, CYP3A4 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 8.378E-07 | 5.068E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, RAB9A |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.936E-06 | 1.453E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 4.300E-06 | 2.012E-03 | CYP19A1, CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 4.435E-06 | 2.012E-03 | CYP2D6, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.435E-06 | 2.012E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 5.410E-06 | 2.404E-03 | CYP19A1, CYP3A4, ESR1 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.864E-06 | 3.784E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.476E-05 | 5.740E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.213E-05 | 8.166E-03 | CYP1A1, CYP3A4 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.214E-16 | 6.999E-12 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 9.691E-05 | 2.891E-02 | SMN1, SMN2 |
CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 1.144E-04 | 3.236E-02 | SMN1, SMN2 |
CC | GO:0016020; membrane | GO:0031090; organelle membrane | 1.766E-04 | 4.633E-02 | ABCG2, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, LMNA, NPC1, RAB9A |
CC | GO:0043226; organelle | GO:0043231; intracellular membrane-bounded organelle | 1.951E-04 | 4.979E-02 | ABCG2, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP2D6, CYP3A4, ESR1, HSP90AA1, LMNA, MAPT, NPC1, RAB9A, RARA, SMN1, SMN2, TDP1 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.449E-10 | 1.151E-08 | CYP2C9, CYP2D6, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.003E-10 | 1.176E-08 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.006E-09 | 1.098E-07 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.704E-08 | 2.002E-07 | CYP2C9, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.712E-08 | 3.489E-07 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.028E-06 | 8.053E-06 | CYP2C9, CYP1A2, CYP1A1, CYP3A4 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.457E-05 | 9.782E-05 | CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.868E-05 | 1.685E-04 | CYP1A1, CYP1B1, CYP19A1 |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 8.225E-05 | 4.295E-04 | ABCB1, CYP3A4, ABCG2 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.176E-04 | 1.493E-03 | CYP2C9, CYP2D6, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.497E-03 | 9.782E-03 | CYP2C9, CYP2C19 |
09130 Environmental Information Processing | 09131 Membrane transport | hsa02010 | ABC transporters | 1.266E-03 | 5.409E-03 | ABCB1, ABCG2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | KCNA3; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | RARA; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic arthritis | L40.5, M07 | KCNA3; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | RARA; |
NA: NA | Menopausal disorder | NA | ESR1; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CYP19A1; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | RARA; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | RARA; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |